Adaptimmune Therapeutics

Adaptimmune Therapeutics Plc engages in the development of novel cancer immunotherapy products. Its specific peptide enhanced affinity receptor platform enables the engineering of T-cells to target and destroy cancer, including solid tumors. The company was founded by Bent K. Jakobsen, James Julian Noble, and Helena Katrina Tayton-Martin in 2008 and is headquartered in Abingdon, the United Kingdom.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Adaptimmune reports strong Q1 results, eyes market leadership with afami-cel

Adaptimmune Therapeutics shows strong performance and progress in Q1 2024.
Strengths lie in innovative therapies, financial stability, and clear development plans.
Challenges include managing debt impact, FDA processes, and successful product launches.
Opportunities exist in market leadership, upcoming presentations, and growth strategies.

Adaptimmune achieves commercial milestone with Tecelra launch, poised for growth

Adaptimmune's Q2 performance reflects a transformative phase as it transitions into a commercial-stage company with a strong financial position and a focus on innovative cell therapies.
While facing challenges in operational execution and revenue forecasting, the company's strategic strengths lie in its pioneering treatments, robust pipeline, and customer-centric approach.
By capitalizing on opportunities for market expansion, strategic partnerships, and operational optimization, Adaptimmune is poised to drive growth and establish itself as a key player in the cell therapy sector.

Adaptimmune targets breakeven by 2027 with strong sarcoma franchise

Adaptimmune Therapeutics is strategically positioned to achieve operating breakeven by 2027 through significant cost reductions and a focus on their sarcoma franchise with Tecelra and lete-cel.
The company's financial stability, positive trial results, and revenue targets indicate a strong growth trajectory and confidence in their business strategy.
While facing challenges in cost reduction and workforce restructuring, Adaptimmune Therapeutics has opportunities to capitalize on market expansion and product efficacy to drive future growth.
Overall, the company's performance in Q3 reflects a proactive approach to financial sustainability and market competitiveness in the oncology sector.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Adaptimmune Therapeutics Plc is commercial-stage cell therapy company, which focuses on providing novel cell therapies to people with cancer. Its clinical pipeline includes Afami-cel, Lete-cel, and ADP-A2M4CD8. The company was founded by Bent K. Jakobsen, James Julian Noble, and Helena Katrina Tayton-Martin in 2008 and is headquartered in Abingdon, the United Kingdom.

Adaptimmune Therapeutics PLC (ADAP) CEO Adrian Rawcliffe on Q4 2020 Results - Earnings Call Transcript

- Outlined strategy to build integrated cell therapy company and the Company's “2-2-5-2” five-year core value drivers -

Adaptimmune Reports Fourth Quarter / Full Year 2020 Financial Results and Business Update

Immense potential, TCR therapy leader, but early stage. Science looks excellent with some proof of concept but risks, especially toxicity risks, abound.

Adaptimmune: Clear Leader In TCR Therapies Targeting Solid Tumors, Speculative Investment

- SPEARHEAD-1 enrolment on track; planning to launch ADP-A2M4 in 2022 in the US for people with synovial sarcoma -

Adaptimmune to Showcase Market Potential for SPEAR T-cell Portfolio and Pipeline with Multiple Cell Therapy Platforms During Virtual Investor Day

- Data support confidence in SPEARHEAD-1 as a registrational trial -

Durable Responses with ADP-A2M4 in Synovial Sarcoma with Confirmed Responses in 44% of Patients and Disease Control Rate of 94% Presented at CTOS

PHILADELPHIA and OXFORDSHIRE, United Kingdom, Nov. 12, 2020 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in cell therapy to treat cancer, will host a virtual Investor Day on November 20, 2020 at 8AM EST/ 1PM GMT. A link to register is available HERE and further details are on the Investor Relations tab of the Adaptimmune website.

Adaptimmune to Host Virtual Investor Day on Friday, November 20th

- Data support continued development of ADP-A2M4CD8 -

Two Confirmed Responses and Five out of Six Patients with Initial Tumor Reductions from Early Dose Cohorts of SURPASS Trial, Presented at SITC

Trillium Therapeutics

Adaptimmune Therapeutics and Trillium Therapeutics could be big winners for early shareholders.

2 Cancer Stocks That Could Make You Filthy Rich

Adaptimmune Therapeutics plc (ADAP) CEO Adrian Rawcliffe on Q3 2020 Results - Earnings Call Transcript

- Data from Phase 1 Trial with ADP-A2AFP in liver cancer presented at ILC confirm safety profile and demonstrate potential benefit for patients -

Adaptimmune Reports Q3 Financial Results and Business Update

PHILADELPHIA and OXFORDSHIRE, U.K., Oct. 22, 2020 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in cell therapy to treat cancer, will report financial results and provide a business update for Q3 2020, before the U.S. markets open on Thursday, November 5, 2020. Following the announcement, the Company will host a live teleconference and webcast at 8:00 a.m. EST (1:00 p.m. GMT) on the same day (details below).

Adaptimmune to Report Q3 Financial Results and Business Update on Thursday, November 5, 2020

An early abstract release has shareholders in panic mode today.

Why Adaptimmune Therapeutics Stock Is Sinking Today

PHILADELPHIA and OXFORDSHIRE, United Kingdom, Oct. 15, 2020 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (“Adaptimmune”) (Nasdaq: ADAP), a leader in cell therapy to treat cancer is aware of the early release of the abstract entitled “Initial safety, efficacy, and product attributes from the SURPASS trial with ADPA2M4CD8, a SPEAR T-cell therapy incorporating an affinity optimized TCR targeting MAGE-A4 and a CD8α co-receptor” by the Society for the Immunotherapy of Cancer (“SITC”) Conference.

Adaptimmune Provides Full Contents of its SITC Abstract for the Phase 1 SURPASS Trial

Chemocentryx

Kodiak Sciences Inc

Seres Therapeutics

Myovant Sciences

Novavax

Sorrento Therapeutics Inc

The pandemic has raised awareness about the value of biotech across the world. In turn, these biotech stocks will benefit down the road.

7 ‘A-Rated’ Aggressive Biotech Stocks to Gamble On

Following the resurgence from the coronavirus bear market of 2020, Adaptimmune yielded multiple fold gains from its lows earlier in the year.

Adaptimmune Therapeutics: Mega Profitability

PHILADELPHIA and OXFORDSHIRE, United Kingdom, Aug.  28, 2020  (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (“Adaptimmune”)(Nasdaq: ADAP), a leader in cell therapy to treat cancer, presented data from its Phase 1 trial with SPEAR T-cells targeting AFP at the virtual International Liver Congress (ILC). One patient out of four dosed with 5 billion or more cells had a complete response, which was reported previously. The data also demonstrate an acceptable safety profile in patients with hepatocellular carcinoma (HCC).

Promising Data from Phase 1 Trial with ADP-A2AFP in Liver Cancer at the International Liver Congress Confirm Safety Profile and Demonstrate Potential Benefit for Patients

Adaptimmune Therapeutics PLC (ADAP) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

All You Need to Know About Adaptimmune Therapeutics PLC (ADAP) Rating Upgrade to Buy

Adaptimmune Therapeutics plc (ADAP) CEO Adrian Rawcliffe on Q2 2020 Results - Earnings Call Transcript

- Reported responses in multiple solid tumor types during ASCO with updates at upcoming congresses in Q4 -

Adaptimmune Reports Q2 Financial Results and Business Update

PHILADELPHIA and OXFORDSHIRE, United Kingdom, July  23, 2020  (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in cell therapy to treat cancer, announced that the European Medicines Agency (EMA) has granted access to the PRIME initiative to the Company for ADP-A2M4 for the treatment of synovial sarcoma. PRIME access provides enhanced scientific and regulatory support by the EMA to developers of medicines with the potential to significantly address unmet medical needs.

Adaptimmune Granted Access to PRIority MEdicines (PRIME) Regulatory Support by the European Medicines Agency for ADP-A2M4 for the Treatment of Synovial Sarcoma

PHILADELPHIA and OXFORDSHIRE, United Kingdom, July  22, 2020  (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in cell therapy to treat cancer, will report financial results and provide a business update for Q2 2020, before the U.S. markets open on Thursday, August 6, 2020. Following the announcement, the Company will host a live teleconference and webcast at 8:00 a.m. EDT (1:00 p.m. BST) on the same day (details below).

Adaptimmune to Report Q2 Financial Results and Business Update on Thursday, August 6, 2020

As of late, it has definitely been a great time to be an investor in Adaptimmune Therapeutics plc (ADAP).

Adaptimmune Therapeutics plc (ADAP) Shares March Higher, Can It Continue?

Adaptimmune Therapeutics (ADAP) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

How Adaptimmune Therapeutics (ADAP) Stock Stands Out in a Strong Industry

Can an early-stage cancer immunotherapy company deliver riches to shareholders?

News for Adaptimmune Therapeutics Stock (ADAP)